Alpha Tau Medical (DRTS) Net Income towards Common Stockholders (2021 - 2026)

Alpha Tau Medical (DRTS) has reported Net Income towards Common Stockholders for 6 consecutive years, with $22.9 million the latest figure, recorded in Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 166.98% year-over-year to $22.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56.8 million (up 75.67% YoY) and the FY2025 annual result came in at $42.4 million, up 33.55% from the prior year.
• Net Income towards Common Stockholders advanced to $22.9 million in Q1 2026 per DRTS's latest filing, from $12.2 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for DRTS reached as high as $25.7 million in Q1 2022 and fell as low as $2.0 million in Q2 2022.
• A 5-year average of $9.4 million and a median of $8.1 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders sank 71.42% — and 2023, when it surged 334.88%.
• Year by year, Net Income towards Common Stockholders stood at $3.4 million in 2022, then soared by 116.78% to $7.3 million in 2023, then increased by 28.89% to $9.5 million in 2024, then increased by 28.86% to $12.2 million in 2025, then soared by 87.93% to $22.9 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $22.9 million, $12.2 million, and $11.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.